Literature DB >> 8305141

Botulinum a toxin treatment of hemifacial spasm and blepharospasm.

Y C Park1, J K Lim, D K Lee, S D Yi.   

Abstract

We studied the effects of botulinum A toxin in 101 patients with hemifacial spasm and 11 patients with blepharospasm in an open trial and double blind manner. All patients in the open trial and 6 patients in the double blind trial improved after the first injection of botulinum toxin. There was no improvement with placebo. The peak effect ranged from one to 6 days after injection and mean peak effect was 3.6 days in blepharospasm, and 4 days in hemifacial spasm. Of 144 treatments, 98.6% had excellent results, (below grade I). The duration of beneficial effect ranged 11 to 40 weeks (mean 16.5 weeks) in hemifacial spasm and 9 to 30 weeks (mean 14.2 weeks) in blepharospasm. Complications were encountered in 63.4% in hemifacial spasm and 72.7% in blepharospasm. The common side effects were dry eyes, mouth droop, ptosis and lid edema in order of frequency. These side effects were mild and resolved spontaneously in 1 to 3 weeks. Botulinum A toxin therapy is effective and convenient, and the treatment of choice for patients with hemifacial spasm and blepharospasm.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8305141      PMCID: PMC3053713          DOI: 10.3346/jkms.1993.8.5.334

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  16 in total

Review 1.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

2.  Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment.

Authors:  Libin Xiao; Yougui Pan; Xiaolong Zhang; Yong Hu; Li Cai; Zhiyu Nie; Lizhen Pan; Bing Li; Yijing He; Lingjing Jin
Journal:  Neurol Sci       Date:  2016-07-18       Impact factor: 3.307

3.  Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.

Authors:  A R Bentivoglio; A Fasano; T Ialongo; F Soleti; S Lo Fermo; A Albanese
Journal:  Neurotox Res       Date:  2009-02-24       Impact factor: 3.911

4.  Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport.

Authors:  Katja Kollewe; Bahram Mohammadi; Reinhard Dengler; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2010-05-01       Impact factor: 3.575

5.  Validation of the Hemifacial Spasm Grading Scale: a clinical tool for hemifacial spasm.

Authors:  Nicola Tambasco; Simone Simoni; Elisa Sacchini; Paolo Eusebi; Erica Marsili; Pasquale Nigro; Elona Brahimi; Federico Paolini Paoletti; Michele Romoli; Paolo Calabresi
Journal:  Neurol Sci       Date:  2019-05-10       Impact factor: 3.307

Review 6.  Botulinum toxin in hemifacial spasm: the challenge to assess the effect of treatment.

Authors:  Bettina Wabbels; Peter Roggenkämper
Journal:  J Neural Transm (Vienna)       Date:  2012-01-10       Impact factor: 3.575

7.  Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D M Simpson; A Blitzer; A Brashear; C Comella; R Dubinsky; M Hallett; J Jankovic; B Karp; C L Ludlow; J M Miyasaki; M Naumann; Y So
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

8.  Botulinum toxin type A therapy for blepharospasm.

Authors:  Gonçalo S Duarte; Filipe B Rodrigues; Raquel E Marques; Mafalda Castelão; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2020-11-19

Review 9.  Botulinum toxin in the treatment of blepharospasm and hemifacial spasm.

Authors:  C Kenney; J Jankovic
Journal:  J Neural Transm (Vienna)       Date:  2007-06-11       Impact factor: 3.575

10.  Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.

Authors:  Jin Sook Yoon; Jae Chan Kim; Sang Yeul Lee
Journal:  Korean J Ophthalmol       Date:  2009-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.